Physician profile
Frank Tan
NPI 1285729723
$1,490.42
in general payments reported to CMS, 2019-2025
11 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Addiction Psychiatry provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $208 · 2021: $241 · 2022: $62.27 · 2023: $90.51 · 2024: $160 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $491.84 | 2019-2024 | Rexulti |
| Allergan, INC. | $295.55 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.61 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $130.69 | 2019-2020 | |
| Abbvie INC. | $116.86 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.88 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $87.55 | 2024 | Rexulti |
| Harmony Biosciences LLC | $85.62 | 2025 | |
| Sunovion Pharmaceuticals INC. | $32.59 | 2019-2020 | |
| Bausch Health US, LLC | $14.73 | 2020 | |
| Shire North American Group INC | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.